

E.8 Corticosteroids (oral hydrocortisone or fludrocortisone, nasal flunisolide) versus placebo

Figure 55: Quality of Life: SF36 at 6 weeks (fludrocortisone)







Figure 56: Fatigue: fatigue on VAS 0-10 at 6 weeks (fludrocortisone)**Figure 57: Fatigue: Chronic Fatigue Syndrome Severity Rating at 4-8 weeks (nasal flunisolide)****Figure 58: Fatigue: Profile of Mood States – fatigue at 11 weeks (fludrocortisone)**




Figure 59: Fatigue: Profile of Mood States - fatigue at 12 weeks (hydrocortisone)**Figure 60: Fatigue: Profile of Mood States – vigour at 11 weeks (fludrocortisone)****Figure 61: Fatigue: Profile of Mood States - vigour at 12 weeks (hydrocortisone)**




Figure 62: Fatigue: Wood Mental Fatigue Inventory at 11 weeks (fludrocortisone)**Figure 63: Physical function: SF36 physical function at 11 weeks (fludrocortisone)****Figure 64: Adverse events: Adverse events leading to study withdrawal at 6 weeks (fludrocortisone)**




Figure 65: Adverse events: adverse effects / adverse events at 6-11 weeks (fludrocortisone)**Figure 66: Adverse events: any adverse reaction at 12 weeks (hydrocortisone)****Figure 67: Psychological status: SF36 mental health at 11 weeks (fludrocortisone)**




Figure 68: Psychological status: Beck Depression Inventory at 11 weeks (fludrocortisone)**Figure 69: Psychological status: Beck Depression Inventory at 12 weeks (hydrocortisone)****Figure 70: Psychological status: Profile of Mood States - anger, at 12 weeks (hydrocortisone)**





Figure 71: Psychological status: Profile of Mood States - anxiety, at 12 weeks (hydrocortisone)**Figure 72: Psychological status: Profile of Mood States - confusion, at 12 weeks (hydrocortisone)****Figure 73: Psychological status: Profile of Mood States - depression, at 12 weeks (hydrocortisone)****Figure 74: Psychological status: Symptom checklist-90-R general sensitivity index at 12 weeks (hydrocortisone)**




Figure 75: Psychological status: Symptom checklist-90-R positive symptom distress index at 12 weeks (hydrocortisone)**Figure 76: Psychological status: Symptom checklist-90-R positive symptom total at 12 weeks (hydrocortisone)****Figure 77: Psychological status: Hamilton Depression Rating Scale at 12 weeks (hydrocortisone)**




Figure 78: Psychological status: Positive and negative effect scale (PANAS) positive affect at 6 weeks (fludrocortisone)**Figure 79: Activity levels: activity scale at 12 weeks (hydrocortisone)****Figure 80: Activity levels: distance before exhausted (ordinal scale) at 6 weeks (fludrocortisone)**



Figure 81: Activity levels: Duke Activity Status Index at 11 weeks (fludrocortisone)**Figure 82: Cognitive function: Reaction time (secs) at 6 weeks (fludrocortisone)**


Figure 83: Cognitive function: VAS 0-10 at 6 weeks (fludrocortisone)



Figure 84: Pain: pain on VAS 0-10 at 6 weeks (fludrocortisone)**Figure 85:** Sleep quality: unrefreshing sleep on VAS 0-10 at 6 weeks (fludrocortisone)




Figure 86: Sleep quality: Functional Outcomes of Sleep Questionnaire at 4-8 weeks (nasal flunisolide)**Figure 87: Exercise performance measure: Treadmill time (mins) at 6 weeks (fludrocortisone)****Figure 88: Symptom scales: Wellness scale at 11 weeks (fludrocortisone)**



Figure 89: Symptom scales: Wellness scale at 12 weeks (hydrocortisone)**Figure 90: Symptom scales: Sickness Impact Profile at 12 weeks (hydrocortisone)**

Figure 91: Symptom scales: VAS 0-10 at 6 weeks